Jeff Michael Michalski

Jeff Michael Michalski's AcademicInfluence.com Rankings

Medical

#3154

World Rank

#3609

Historical Rank

Oncology

#216

World Rank

#224

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Jeff Michael Michalski Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jeff Michael Michalski's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Stereotactic body radiation therapy for inoperable early stage lung cancer. (2010) (2246)
Quality of life and satisfaction with outcome among prostate-cancer survivors. (2008) (1335)
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. (2007) (868)
Treatment of Non‐Metastatic Muscle‐Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (2017) (612)
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. (2013) (411)
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. (2016) (410)
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. (2012) (379)
RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. (2009) (360)
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. (2010) (324)
Predicting dose-volume histograms for organs-at-risk in IMRT planning. (2012) (323)
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. (2003) (300)
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (297)
Prediction of erectile function following treatment for prostate cancer. (2011) (284)
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. (2000) (283)
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. (2003) (270)
Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. (2013) (267)
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. (2016) (266)
Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. (2015) (256)
Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. (2017) (251)
Adaptive modification of treatment planning to minimize the deleterious effects of treatment setup errors. (1997) (243)
Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. (2017) (234)
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (230)
Online Magnetic Resonance Image Guided Adaptive Radiation Therapy: First Clinical Applications. (2016) (230)
Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial (2018) (211)
Positron tomographic assessment of androgen receptors in prostatic carcinoma (2005) (211)
Basal cell and squamous cell skin cancers. (2010) (207)
Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. (2003) (201)
Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer (2014) (188)
Childhood and adolescent thyroid carcinoma (2002) (183)
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. (2004) (183)
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. (2018) (180)
Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. (2013) (174)
Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. (2007) (163)
A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. (2013) (162)
Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. (2004) (153)
Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). (2002) (146)
Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial (2018) (146)
Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. (2010) (142)
Penile cancer: Clinical Practice Guidelines in Oncology. (2013) (139)
Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. (2004) (137)
No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. (2014) (137)
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. (2003) (136)
Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. (2016) (135)
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. (2012) (134)
Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. (2005) (133)
Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. (2005) (129)
Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2). (2017) (124)
Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer (2006) (119)
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. (2005) (118)
Clinical evaluation of a commercial orthopedic metal artifact reduction tool for CT simulations in radiation therapy. (2012) (117)
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. (2018) (117)
Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system (2017) (115)
Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. (2002) (114)
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). (2015) (114)
A critical evaluation of the planning target volume for 3-D conformal radiotherapy of prostate cancer. (1998) (114)
Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non–Small Cell Lung Cancer (2018) (113)
Long-term outcome in children treated for craniopharyngioma with and without radiotherapy. (2008) (109)
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. (2005) (109)
Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. (2002) (107)
Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. (2009) (107)
Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126. (2015) (104)
National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. (2018) (101)
The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. (2010) (101)
Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. (2009) (98)
American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology (2017) (96)
Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial (2018) (94)
Tools for consensus analysis of experts' contours for radiotherapy structure definitions. (2010) (93)
Adjuvant radiation therapy for rectal carcinoma: predictors of outcome. (1995) (93)
Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages. (2016) (92)
Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. (2004) (89)
Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. (2003) (88)
Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A 4.5-Year Clinical Experience. (2018) (85)
Comparative effectiveness study of patient‐reported outcomes after proton therapy or intensity‐modulated radiotherapy for prostate cancer (2014) (85)
A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. (2010) (84)
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. (2019) (83)
Standardizing naming conventions in radiation oncology. (2012) (83)
Initial Report of NRG Oncology/RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate-Risk Prostatic Carcinoma (2016) (82)
Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91-04. (2000) (81)
Highly Efficient Training, Refinement, and Validation of a Knowledge-based Planning Quality-Control System for Radiation Therapy Clinical Trials. (2017) (79)
Estimation of α/β for late rectal toxicity based on RTOG 94-06. (2011) (78)
Postoperative radiation therapy for grade II and III intracranial ependymoma. (2005) (77)
Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. (2007) (76)
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. (2013) (76)
Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. (2003) (75)
Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison. (2000) (74)
Hematologic Safety of Radium‐223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial (2017) (72)
Quality of Intensity Modulated Radiation Therapy Treatment Plans Using a ⁶⁰Co Magnetic Resonance Image Guidance Radiation Therapy System. (2015) (70)
RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? (2003) (70)
Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation. (1998) (68)
Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study. (2004) (67)
Bladder cancer. (2013) (67)
Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. (2015) (67)
Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features (2018) (66)
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. (2016) (66)
Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. (2004) (65)
Event (error and near-miss) reporting and learning system for process improvement in radiation oncology. (2010) (65)
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. (2012) (64)
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. (2016) (64)
Glioblastoma in children: a single-institution experience. (2011) (63)
Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma (2013) (63)
Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. (2010) (63)
Primary central nervous system lymphoma: analysis of prognostic variables and patterns of treatment failure. (1990) (62)
Is weekly port filming adequate for verifying patient position in modern radiation therapy? (1994) (62)
Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines (2016) (61)
Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. (2007) (59)
Tumor and target delineation: current research and future challenges. (1995) (57)
A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. (2020) (57)
Biochemical and clinical significance of the posttreatment prostate‐specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone (2006) (57)
The use of on-line image verification to estimate the variation in radiation therapy dose delivery. (1993) (56)
Management of primary skin cancer during a pandemic: Multidisciplinary recommendations (2020) (56)
Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. (2014) (56)
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. (2015) (56)
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analy (2009) (55)
Long term outcome with post-operative radiation therapy for spinal canal ependymoma (2007) (55)
Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. (2012) (54)
A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). (2017) (53)
Preliminary patient‐reported outcomes analysis of 3‐dimensional radiation therapy versus intensity‐modulated radiation therapy on the high‐dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial (2015) (53)
Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. (2010) (52)
Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. (2017) (49)
Design of a fully integrated three-dimensional computed tomography simulator and preliminary clinical evaluation. (1994) (49)
Results of COG ACNS0331: A Phase III Trial of Involved-Field Radiotherapy (IFRT) and Low Dose Craniospinal Irradiation (LD-CSI) with Chemotherapy in Average-Risk Medulloblastoma: A Report from the Children's Oncology Group (2016) (49)
Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. (1996) (48)
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer. (2020) (47)
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. (2020) (46)
Method to plan, administer, and verify supine craniospinal irradiation (2002) (46)
Three dimensional conformal radiation therapy in pediatric parameningeal rhabdomyosarcomas. (1995) (46)
Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. (2018) (45)
Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? (2003) (44)
An analysis of intratreatment and intertreatment displacements in pelvic radiotherapy using electronic portal imaging. (1996) (44)
Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. (2018) (43)
Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: results of RTOG 94-12. (1998) (42)
Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. (2018) (42)
Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis. (2005) (42)
Initial Results of a Phase 3 Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126) (2014) (41)
Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children (2015) (40)
Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison (2011) (40)
Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. (2011) (39)
Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. (2016) (39)
Radiation exposure to family and household members after prostate brachytherapy. (2003) (39)
Fit of a Generalized Lyman Normal-Tissue Complication Probability (NTCP) Model to Grade ≥ 2 Late Rectal Toxicity Data From Patients Treated on Protocol RTOG 94-06 (2007) (39)
Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. (2020) (38)
Impact of Elapsed Treatment Time on Outcome of External‐Beam Radiation Therapy for Localized Carcinoma of the Prostate (2004) (38)
NCTN Assessment on Current Applications of Radiomics in Oncology. (2019) (38)
RTOG physician and research associate attitudes, beliefs and practices regarding clinical trials: implications for improving patient recruitment. (2010) (38)
NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. (2016) (38)
Initial experience with quality assurance of multi-institutional 3D radiotherapy clinical trials. A brief report. (1998) (37)
Early toxicity predicts long-term survival in high-grade glioma (2011) (37)
An evaluation of departmental radiation oncology incident reports: anticipating a national reporting system. (2013) (37)
Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03 (2009) (37)
Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database (2018) (37)
Secondary malignancy among seminoma patients treated with adjuvant radiation therapy. (1995) (36)
Prospective clinical evaluation of an electronic portal imaging device. (1996) (36)
Phase I results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with Inoperable NSCLC (2005) (35)
Stereotactic Body Radiation Therapy for Medically Inoperable Early-stage Lung Cancer Patients: Analysis of RTOG 0236 (2009) (35)
Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group. (2011) (35)
Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. (2013) (34)
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. (2013) (34)
Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial (2019) (34)
Bladder cancer, version 3.2020 (2020) (34)
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. (2017) (34)
Intensity-modulated radiotherapy for prostate cancer (2018) (33)
Cost benefit of emerging technology in localized carcinoma of the prostate. (1997) (33)
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. (2020) (33)
Errors in radiation oncology: A study in pathways and dosimetric impact (2005) (33)
The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803. (2013) (32)
Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. (2017) (31)
Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma (2021) (31)
Toxicity Analysis of RTOG 0236 Using Stereotactic Body Radiation Therapy to Treat Medically Inoperable Early Stage Lung Cancer Patients (2007) (31)
An evaluation of two methods of anatomical alignment of radiotherapy portal images. (1993) (31)
A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer. (2015) (31)
Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408. (2015) (30)
Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. (2006) (30)
Errors in radiation oncology: a study in pathways and dosimetric impact. (2003) (29)
Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. (2002) (29)
Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06. (2012) (29)
Practical method of adaptive radiotherapy for prostate cancer using real-time electromagnetic tracking. (2009) (28)
Adaptive radiation therapy for postprostatectomy patients using real-time electromagnetic target motion tracking during external beam radiation therapy. (2013) (28)
Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines. (2020) (27)
Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint. (2001) (27)
Preliminary Analysis of 3D-CRT vs. IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial: Toxicity Report (2011) (27)
A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment. (2012) (26)
Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group. (2021) (26)
Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder. (2017) (26)
Distance to Radiation Facility and Treatment Choice in Early-Stage Breast Cancer. (2016) (25)
Multi-institutional clinical trials: 3-D conformal radiotherapy quality assurance. Guidelines in an NCI/RTOG study evaluating dose escalation in prostate cancer radiotherapy. (1996) (25)
A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. (2018) (24)
Oligodendrogliomas in children (2011) (24)
External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. (2017) (24)
Future vision for the quality assurance of oncology clinical trials (2013) (24)
Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma (2019) (24)
Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II–IV, 1978–1997: Report from the Children's Oncology Group (2008) (24)
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients (2018) (24)
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (2006) (23)
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. (2013) (23)
The Efficacy of Radiation Therapy in the Management of Grade I Astrocytomas (2005) (23)
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children’s oncology group (2006) (23)
NRG Oncology RTOG 0415: A Randomized Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer (2016) (22)
Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. (2017) (22)
The CT-simulation 3-D treatment planning process. (1996) (21)
Patient-Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase 2 Study Evaluating 2 Ultrahypofractionated Regimens (UHRs) for Prostate Cancer (2016) (21)
Satisfaction with information used to choose prostate cancer treatment. (2014) (20)
Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update. (2002) (20)
MR-Guided Adaptive Radiotherapy for Bladder Cancer (2021) (20)
The world's first single-room proton therapy facility: Two-year experience. (2016) (20)
Eliminating inconsistencies in simulation and treatment planning orders in radiation therapy. (2010) (20)
A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database (2018) (19)
AAPM Task Group 263: Tackling Standardization of Nomenclature for Radiation Therapy (2015) (19)
Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). (2010) (18)
External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. (2015) (18)
Current calibration, treatment, and treatment planning techniques among institutions participating in the Children's Oncology Group. (2003) (18)
A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate (2019) (18)
A multi-institutional analysis of adjuvant and salvage radiotherapy after radical prostatectomy (2004) (18)
The cumulative verification image analysis tool for offline evaluation of portal images. (1995) (18)
ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. (2009) (18)
Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer. (2000) (17)
Association of 1p/19q Codeletion and Radiation Necrosis in Adult Cranial Gliomas After Proton or Photon Therapy. (2018) (17)
Standardizing Nomenclatures in Radiation Oncology (2018) (16)
Adjuvant radiation therapy, androgen deprivation, and docetaxel for high‐risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621 (2017) (15)
MP72-01 IMPROVEMENTS IN FREEDOM FROM PROGRESSION WITH SHORT TERM ANDROGEN DEPRIVATION THERAPY AND PELVIC LYMPH NODE TREATMENT ADDED TO PROSTATE BED SALVAGE RADIOTHERAPY: THE NRG ONCOLOGY/RTOG 0534 SPPORT TRIAL (2019) (15)
Imaging and Data Acquisition in Clinical Trials for Radiation Therapy. (2016) (15)
Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial (2019) (15)
Image-Guided Radiation Therapy Committee (2001) (15)
Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment (2017) (15)
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. (2019) (15)
Long-term results of NRG Oncology/RTOG 0321 a phase II trial of combined high dose rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate. (2019) (14)
Dose escalation in locally advanced carcinoma of the prostate. (2003) (14)
Inter-institutional variation of implant activity for permanent prostate brachytherapy. (2008) (14)
Preliminary report of toxicity following 3D Conformal Radiation Therapy (3DCRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy) (2001) (14)
Physician resource utilization in radiation oncology: a model based on management of carcinoma of the prostate. (1998) (14)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Image-Guided Radiation Therapy Committee. (2001) (13)
Clinical implementation of dose-volume histogram predictions for organs-at-risk in IMRT planning (2014) (13)
Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. (2004) (13)
Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408 (2017) (13)
Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level IV (2002) (13)
The effect of age on outcome in prospective, phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- chemotherapy in locally advanced (LA) head and neck cancer (HNC). (2015) (13)
Does the evidence support the enthusiasm over 3D conformal radiation therapy and dose escalation in the treatment of prostate cancer? (2001) (13)
Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer. (2014) (13)
New trends in prostatic cancer research. Three-dimensional conformal radiation therapy (3-D CRT), brachytherapy, and new therapeutic modalities. (2000) (13)
Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors (2021) (12)
Bladder cancer. (2009) (12)
MB-109PRELIMINARY RESULTS OF COG ACNS0331: A PHASE III TRIAL OF INVOLVED FIELD RADIOTHERAPY (IFRT) AND LOW DOSE CRANIOSPINAL IRRADIATION (LD-CSI) WITH CHEMOTHERAPY IN AVERAGE RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (2016) (12)
First Reported Case of Pediatric Radiation Treatment With Magnetic Resonance Image Guided Radiation Therapy (2019) (12)
A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902. (2010) (12)
Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. (2020) (12)
Comparison of dose decrement from intrafraction motion for prone and supine prostate radiotherapy. (2012) (12)
ACR–ASTRO Practice Parameter for Communication (2020) (12)
Radiation therapy in the treatment of localized prostate cancer: an alternative to an emerging consensus. (1995) (11)
Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis (2017) (11)
Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06. (2012) (11)
Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer (2019) (11)
The biochemical and clinical significance of the post-treatment PSA bounce for prostate cancer patients treated with external beam radiation therapy alone: A multi-institutional pooled analysis (2004) (11)
Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. (2016) (11)
Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer. (2020) (10)
Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience (2017) (10)
VA-Radiation Oncology Quality Surveillance Program. (2020) (10)
Clinical Outcomes and Prognostic Features of Angiosarcoma: Significance of Prior Radiation Therapy. (2019) (10)
Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992. (2020) (10)
Bone Health and Bone-Targeted Therapies for Prostate Cancer: American Society of Clinical Oncology Endorsement Summary of a Cancer Care Ontario Guideline. (2020) (9)
Basal cell and squamous cell skin cancers. Clinical practice guidelines in oncology. (2004) (9)
Continued Benefit to Rectal Separation for Prostate RT: Final Results of a Phase III Trial (2016) (9)
Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT (2014) (9)
Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003. (2021) (9)
Radiation therapy for increasing prostate-specific antigen levels after radical prostatectomy. (2003) (9)
Automatic CT simulation optimization for radiation therapy: A general strategy. (2014) (9)
Palliative radiation therapy (RT) for prostate cancer patients with bone metastases at diagnosis: A hospital‐based analysis of patterns of care, RT fractionation scheme, and overall survival (2018) (8)
Isolated CNS relapse following stem cell transplantation for juvenile myelomonocytic leukemia. (2003) (8)
Update of toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 (2000) (8)
Report dose-to-medium in clinical trials where available; a consensus from the global Harmonisation group to maximize consistency. (2021) (8)
Do not count out external-beam radiation therapy for high-risk prostate cancer. (2010) (8)
Preliminary Analysis of RTOG 9902: Increased Toxicity Observed with the Use of Adjuvant Chemotherapy (2005) (8)
Dermatofibrosarcoma protuberans. (2022) (8)
Innovations in Three-Dimensional Treatment Planning and Quality Assurance (1998) (8)
Magnetic resonance imaging-based treatment planning for prostate cancer: Use of population average tissue densities within the irradiated volume to improve plan accuracy. (2015) (7)
An analysis of appropriate delivery of postoperative radiation therapy for endometrial cancer using the RAND/UCLA Appropriateness Method: Executive summary (2015) (7)
NRG Oncology/RTOG 0415, Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer: Prostate-Specific Quality of Life Results (2016) (7)
Stereotactic Body Radiation Therapy for the Treatment of Primary Cardiac Angiosarcoma Causing Hemodynamic Instability. (2019) (7)
Clinical assessment of outcome of prostate cancer (TCP, NTCP). (2005) (7)
Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy (2020) (7)
The Dawn of a New Era: First Ever MR-IGRT Treatments – Initial Experiences and Future Implications (2014) (7)
Variability of prostate brachytherapy preimplant dosimetry: A multi-institutional analysis (2005) (7)
Mean dose of radiation to the bulb of the penis correlates with risk of impotence at 24 months: Preliminary analysis of Radiation Therapy Oncology Group (RTOG) phase I/II dose escalation trial 9406☆ (2000) (7)
The Importance of Temporary Telehealth Parity Laws to Improve Public Health During COVID-19 and Future Pandemics (2020) (7)
Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521. (2020) (7)
A comparative study based on image quality and clinical task performance for CT reconstruction algorithms in radiotherapy. (2016) (6)
Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer (2019) (6)
System mapping of complex healthcare processes using IDEF0: a radiotherapy example (2010) (6)
Optimal Equations for Describing the Relationship Between Prostate Volume, Number of Sources, and Total Activity in Permanent Prostate Brachytherapy (2009) (6)
Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma (2021) (6)
A method to evaluate the impact of daily treatment variation on 3-d dimensional dose distributions (1993) (6)
Uncertainties in radiation therapy: target volume definition in prostate cancer. (2003) (6)
Adjuvant Radiation, Androgen Deprivation, and Docetaxel for High-Risk Prostate Cancer Postprostatectomy: Results of RTOG 0621 (2014) (6)
Phase I/II conformal three-dimensional radiation therapy dose escalation study in patients with supratentorial glioblastoma multiforme: Report of the radiation therapy oncology group 98–03 protocol (2004) (6)
Implementing a Novel Remote Physician Treatment Coverage Practice for Adaptive Radiation Therapy During the Coronavirus Pandemic (2020) (6)
18F-Fluciclovine positron emission tomography in men with biochemical recurrence of prostate cancer after radical prostatectomy and planning to undergo salvage radiotherapy: Results from LOCATE. (2020) (6)
The Impact of MRI Training on Improvement of CT Based Post Implant Dosimetry: A Six Physician Study (2005) (6)
Prostate Cancer-Specific Mortality and Survival Outcomes for Salvage Radiation Therapy After Radical Prostatectomy. (2016) (6)
Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. (2021) (6)
Oral Scientific SessionsA Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiation Therapy (NRG/RTOG0526): Initial Report of Late Toxicity Outcome (2017) (6)
Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial. (2021) (5)
1192: A Nomogram to Predict the Outcome of Salvage Radiotherapy (RT) for Biochemical Recurrence (BCR) Following Radical Prostatectomy (RP) (2006) (5)
On-line image verification in radiation therapy: an early USA experience. (1993) (5)
Impact of Facility Radiation Patient Volume on Overall Survival in Patients with Muscle Invasive Bladder Cancer Undergoing Trimodality Bladder Preservation Therapy (2019) (5)
Quality of life following 3D conformal radiation therapy or permanent interstitial brachytherapy for localized prostate cancer (2001) (5)
Practical Implications of Ferromagnetic Artifacts in Low-field MRI-guided Radiotherapy (2018) (5)
1011 : A Review of the Activities of the ITC in Support of RTOG Advanced Technology Clinical Trials (2006) (5)
Validation of a Knowledge-Based Automated Planning System in Cervical Cancer As a Clinical Trial Quality System (2015) (5)
2187 Novel method to plan, administer, and verify craniospinal axis irradiation (1997) (5)
Does Adjuvant Hormonal Therapy Improve Freedom From Biochemical Relapse in Prostate Cancer Patients Receiving Dose-Escalated Radiation Therapy? An Analysis of RTOG 94-06 (2007) (5)
Dermatofibrosarcoma protuberans. Clinical practice guidelines in oncology. (2004) (5)
The Electronic View Box: a software tool for radiation therapy treatment verification. (1995) (5)
SU-E-P-22: AAPM Task Group 263 Tackling Standardization of Nomenclature for Radiation Therapy (2015) (5)
Transperineal ultrasound-guided implantation of electromagnetic transponders in the prostatic fossa for localization and tracking during external beam radiation therapy. (2014) (4)
285 OVERALL AND CANCER SPECIFIC SURVIVAL FOLLOWING DEFINITIVE THERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER IN THE PROSTATE-SPECIFIC ANTIGEN ERA (2010) (4)
No Clinically Significant Changes in Pulmonary Function Following Stereotactic Body Radiation Therapy (SBRT) Among Medically Inoperable Patients With Early Stage Peripheral Non-small Cell Lung Cancer: An Analysis of RTOG 0236 (2012) (4)
Preliminary Analysis of 3D-CRT vs. IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial: Patient Reported Outcomes (2011) (4)
Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer. (2019) (4)
Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. (2006) (4)
Impact of Prior Docetaxel, Extent of Disease (EOD), and Prior Bisphosphonates (Bp) on Hematologic (Heme) Safety of Radium-223 Dichloride (Ra-223) From ALSYMPCA (2014) (4)
Radiotherapy plus chemotherapy for head and neck cancer. (1993) (4)
The Simulation Process in the Determination and Definition of the Treatment Volume and Treatment Planning (2006) (4)
Dose Volume Analysis of Grade 2+ Late GI Toxicity on RTOG 0126 After High-dose 3DCRT or IMRT (2012) (4)
11: Impact of Prostate Cancer Patient Treatment Outcome on HRQOL and Satisfaction with Cancer Care among Their Spouses (2007) (4)
The use of daily portal images to estimate the variation in dose delivery (1991) (4)
Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG/RTOG -0526) (2020) (4)
Trends in Surgical Management of Benign Prostatic Hyperplasia (2011) (4)
External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial (2015) (4)
Long-Term Update of NRG Oncology RTOG 94-08 (2018) (4)
Phase 2 Multicenter Clinical Trial of Bone Marrow-Sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage IB-IVA Cervical Cancer. (2016) (3)
Spatially fractionated stereotactic body radiotherapy (Lattice SBRT) for large tumors (2020) (3)
Poster Viewing AbstractSuboptimal Treatment Planning Adds Substantial Risk of Normal Tissue Complication: A Secondary Study on RTOG 0126 (2014) (3)
Predicting outcome after PSA failure in prostate cancer patients treated by radiation. Who needs salvage therapy (2004) (3)
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 (2021) (3)
The effect on toxicity of induction hormonal therapy in prostate cancer patients receiving dose escalated 3D conformal radiation therapy on RTOG 94-06 (2002) (3)
American brachytherapy society recommendations for clinical implementation of nist-1999 standards for palladium-103 brachytherapy. Authors' reply (2001) (3)
Chapter 53 – Prostate Cancer (2016) (3)
Development and Implementation of Quality Measures for the Survey Based Performance Assessment of Radiation Therapy in the VA (2017) (3)
Predictors of radiotherapy-related gastrointestinal toxicity from anal cancer DP-IMRT: Secondary analysis of RTOG 0529. (2014) (3)
Prospective study evaluating the use of IV contrast on IMRT treatment planning for lung cancer. (2014) (3)
In regard to Beyer, Nath, and Butler et al. IJROBP 2000;47:273-275. (2001) (3)
Cost-Effectiveness of Proton Therapy Compared to Photon Therapy in the Management of Pediatric Medulloblastoma (2013) (3)
An analysis of intratreatment and intertreatment variations in pelvic patient positioning using electronic portal imaging (1994) (3)
Radium-223 Dichloride (Ra-223) Impact on Skeletal-Related Events, External Beam Radiation Therapy (EBRT), and Pain in Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases: Updated Results From the Phase 3 ALSYMPCA Trial (2013) (3)
Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving postprostatectomy IMRT. (2015) (3)
Adaptive MR-Guided Stereotactic Body Radiation Therapy (AMR-SBRT) for Oligometastatic or Unresectable Primary Abdominal Malignancies: Results of a Prospective Phase I Trial (2016) (3)
Adjuvant radiation, androgen deprivation, and docetaxel for high-risk prostate cancer post-prostatectomy: Results of RTOG 0621. (2014) (3)
Clinical outcomes and prognostic factors in 4839 patients treated with external radiotherapy for stage T1-T2 prostate cancer (2004) (3)
Dose-Volume Analyses of Grade ≥ 2 Late Rectal Toxicity Among Patients Treated on Protocol RTOG 94-06 (2007) (2)
PDCT-05. MOLECULAR DIAGNOSTICS REVEAL 60% HIGHER SURVIVAL FOR MOLECULARLY-VERIFIED VERSUS HISTOPATHOLOGICALLY-DIAGNOSED PEDIATRIC SUPRATENTORIAL CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS AND PINEOBLASTOMAS; A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP ACNS0332 TRIAL (2017) (2)
Bladder Cancer , Version 5 . 2017 Clinical Practice Guidelines in Oncology (2017) (2)
MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (2020) (2)
Introduction: Locally advanced prostate cancer (2003) (2)
Comparative Effectiveness Study of Proton Therapy Versus IMRT for Definitive Treatment of Prostate Cancer Based on Patient-Reported Outcomes (2013) (2)
The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols. (2018) (2)
Evaluating the correlation between early and late quality-of-life declines using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) after definitive stereotactic body radiotherapy, intensity-modulated radiotherapy, or brachytherapy for prostate cancer. (2021) (2)
Influence of radiation therapy (RT) parameters on outcome in children treated for parameningeal rhabdomyosarcoma in the intergroup rhabdomyosarcoma group trials (2002) (2)
2222 Variation in the Definition of Clinical Target Volumes for Postoperative Conformal Radiation Therapy of (2007) (2)
An Electronic Phantom for Testing and Quality Assurance of Dose Volume Histogram Calculations used in Data Analysis for Multi Institutional Clinical Trials (2009) (2)
Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP). (2016) (2)
Benchmark and Performance Evaluation of a Clinical 60Co IMRT Treatment Planning System for Magnetic Resonance Image Guided Radiation Therapy (MR-IGRT) (2014) (2)
PD5-2-4: Phase I/II results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC (2007) (2)
An integrated image/clinical database for outcome studies in 3D conformal radiation therapy* (1998) (2)
Vector Analysis of Bladder Cancer Patient Setup Utilizing a Magnetic Resonance Image Guided Radiation Therapy (MR-IGRT) System (2016) (2)
Radiation Therapy as Definitive Local Treatment in Patients with Limited-Stage Small Cell Carcinoma of the Bladder: Does total dose matter? (2018) (2)
Radiation Oncology Picture Archiving and Communications System: the electronic viewbox. (1996) (2)
Brain tumor committee (2001) (2)
P-603 Phase I results of RTOG L-0117; a phase i/II dose intensificationstudy using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC (2005) (2)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. (2001) (2)
INFLUENCE OF NON-COMPLIANCE WITH RADIATION THERAPY PROTOCOL GUIDELINES AND OPERATIVE BED RECURRENCES FOR CHILDREN WITH RHABDOMYOSARCOMA AND MICROSCOPIC RESIDUAL DISEASE: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (2015) (2)
Review: Brain Metastases in Bladder Cancer (2020) (2)
Comparison of Conventional Versus Hyperfractionated Chemoradiation for Bladder Preservation Treatment of Muscle Invasive Bladder Cancer in the National Cancer Database (2017) (2)
Feasibility of Fiducial-based Electromagnetic Tracking for Postoperative Radiotherapy to the Prostate Bed (2010) (2)
Commentary: Regulating quality? (2011) (2)
Implementation of MR safety program for radiation oncology. (2021) (2)
Long-term results of surgery and post-operative radiation therapy in the curative management of intracranial ependymoma (2002) (2)
Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. (2012) (2)
External Validation of Early Quality of Life (QOL) Declines Correlated with Late QOL after Intensity Modulated, Low Dose Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer within a Prospective Trial (2020) (1)
An electronic viewbox tool for radiation therapy treatment verification (1993) (1)
WE-G-141-01: The Imaging and Radiation Oncology Core (IROC) Group: A Proposed New Clinical Trial Quality Assurance Organization. (2013) (1)
SU-F-T-237: The Imaging and Radiation Oncology Core (IROC) Cooperatives Activities Supporting the NCI's National Clinical Trial Network. (2016) (1)
Radiation Therapy for Prostate Cancer. (2018) (1)
Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials. (2020) (1)
Patterns of toxicities and outcome in children versus adolescents/young adults (AYA) with metastatic rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG) Soft Tissue Sarcoma Committee. (2013) (1)
Pelvic Intensity Modulated Radiation Therapy for High Risk Prostate Cancer (2005) (1)
Counterpoint: Unfair comparisons lead to unwarranted conclusions-Can treatment modalities for localized prostate cancer truly be compared without bias? (2015) (1)
Feasibility of Online Adaptive Planning Using an Onboard Magnetic-Resonance Image Guided Radiation Therapy (MR-IGRT) System (2014) (1)
Radiation therapy in the management of locally advanced prostate cancer (2006) (1)
A Feasibility Study on Incorporating Clinical Trial Quality Assurance Parameters into Outcome Prediction in Head and Neck Radiation Therapy Treatment (2017) (1)
Commissioning and Clinical Implementation of the First Online Adaptive MR Image Guided Radiation Therapy Program (2015) (1)
Distance to nearest radiation facility and treatment choice in early stage breast cancer. (2015) (1)
Treatment Patterns and Survival Outcomes of Patients With Small Cell Carcinoma of the Bladder: A National Cancer Database Analysis (2017) (1)
Chapter 51 – Prostate Cancer (2012) (1)
Definitions of biochemical failure that best predict clinical failure in prostate cancer patients treated with external beam radiation alone- a multi-institutional pooled analysis (2003) (1)
The ABR OLA Part 3 Maintenance of Certification Instrument: Rationale and Summary of Six-Months Experience. (2020) (1)
Bowel and Bladder Function of Men on a Phase 3 Randomized Study of High Versus Standard Dose of 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (2015) (1)
Prognostic risk group stratification for clinical and biochemical failure after external beam radiation of localized prostate cancer (2004) (1)
ACR PRACTICE PARAMETER FOR INTENSITY MODULATED RADIATION THERAPY ( IMRT ) (2016) (1)
Contemporary Update of a Multi-institutional Predictive Nomogram for Salvage Radiation Therapy After Prostatectomy (2015) (1)
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities (2018) (1)
Predictors of Radiotherapy-related GI Toxicity from Anal Cancer DP-IMRT: Secondary Analysis of NRG Oncology RTOG 0529 (2017) (1)
TH‐D‐AUD A‐09: An Error Reporting and Tracking Database Tool for Process Improvement in Radiation Oncology (2008) (1)
Abstract of ASTRO proferred papers, posters, and scientific exhibit to be presentedAdjuvant radiation therapy for rectal carcinoma: Predictors of outcome (1993) (1)
(P19) Single Fraction High Dose Rate Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer: Early Results of a Single Institutional Experience (2018) (1)
Acquisition and Management of Data for Translational Science in Oncology (2019) (1)
Predicting Dose-volume Histograms for Organs at Risk in Intensity Modulated Radiation Therapy Planning (2012) (1)
NCO-03NEUROPSYCHOLOGICAL FUNCTIONING IN THE FIRST YEAR FOLLOWING DIAGNOSIS OF PEDIATRIC MEDULLOBLASTOMA: PRELIMINARY RESULTS FROM CHILDREN'S ONCOLOGY GROUP (COG) ACNS0331 (2015) (1)
Radiation Therapy Oncology Group (RTOG) Consensus Panel Atlas of Musculoskeletal Anatomy (CAMAS) for Soft Tissue Sarcoma of the Extremities (2010) (1)
1772: Prostate Size, Obesity, and Neoadjuvant Hormone Therapy affect Hrqol in a Prospective, Multi-Center Study of Prostatectomy, External Radiotherapy, or Brachytherapy for Prostate Cancer (2007) (1)
Acute neurological toxicity (NT) and long-term outcomes in high-grade glioma RTOG trials. (2010) (1)
Simulation in the Determination and Definition of Treatment Volume and Treatment Planning (2011) (1)
Predictors of Radiotherapy-Related GI Toxicity from Anal Cancer DP-IMRT: Secondary Analysis of RTOG 0529 (2014) (1)
In Regard to Habl et al. (2016) (1)
Impact of Protocol Complexity on Digital Data Integrity Quality Assurance for Clinical Trials Requiring Digital Data Submission (2008) (1)
SU‐E‐J‐167: Iterative Reconstruction Techniques for Radiation Therapy CT Simulations: A Phantom Study (2013) (1)
2204: Early Complications Following Contemporary Brachytherapy for Prostate Cancer in a Multi-Institutional Study at High Volume Health Centers in the US (2006) (1)
An Adaptive Low-Rank Modeling-Based Active Learning Method for Medical Image Annotation (2020) (1)
Impact of Rectal Bleeding on Quality of Life Measures After Prostate Radiation Therapy: Comparison of the EPIC-26 and EPIC-CP Instruments (2015) (1)
Genitourinary cancer committee (2001) (1)
Impact of Post-Prostatectomy Prostate Specific Antigen (PSA) Kinetics on Outcomes of Salvage Radiotherapy (2019) (1)
Effect of PTV and Collimator Margins on Tumor Control for Patients with Stage III Non-small Cell Lung Cancer in NRG Oncology RTOG-0617 (2017) (1)
Parameningeal rhabdomyosarcoma: Results of a pooled analysis from U.S. and European Cooperative Groups. (2011) (1)
Does dose escalation using conformal radiotherapy improve control of prostate cancer? (2005) (1)
Taking Guatemala From Cobalt to IMRT: A Tale of US Agency Collaboration With Academic Institutions and Industry. (2020) (1)
10: NCI Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG/RTOG 0526) (2020) (1)
A Treatment Planning Comparison of Proton Therapy and Intensity Modulated Radiation Therapy (IMRT) for Prostate Cancer Using the Normal Tissue Complication Probability (NTCP) (2016) (1)
Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy. (2017) (1)
Radiation therapy in the management of locally advanced prostate cancer (2006) (1)
SU‐FF‐J‐65: Intrinsic Accuracy of I‐Beam's Coordinate Positioning System Technology (2005) (1)
Dermatofibrosarcoma protuberans. (2012) (1)
NRG Oncology/RTOG 0415, Hypofractionation in Patients with Low-Risk Prostate Cancer: Are Patient Reported Outcomes the Practice Change Tipping Point? (2017) (1)
Health-Related Quality of Life and Cognitive Status in Patients with Glioblastoma Multiforme Receiving Escalating Doses of Conformal Three-Dimensional Radiation on RTOG 9803 (2005) (1)
Concurrent chemo-radiotherapy with proton therapy: reduced toxicity with comparable oncological outcomes vs photon chemo-radiotherapy (2020) (1)
Online Adaptive Magnetic Resonance–Guided (OAMR)-Stereotactic Body Radiation Therapy for Abdominal Malignancies: Prospective Dosimetric Results from a Phase 1 Trial (2016) (1)
2090 Radiation therapy oncology group: 3-D CRT quality assurance guidelines (1995) (1)
PO-1294: Consistency of OAR delineation for clinical trials: A Global Harmonization Group Consensus (2020) (1)
New Developments in Radiation Oncology. (2015) (1)
2183 Efficacy of total lymphoid irradiation for chronic allograft rejection following double lung transplantation (1997) (0)
TRUS Guided Intraoperative Prostate Seed Implantation Based on Preplanning (2008) (0)
SU‐E‐J‐150: Applicability of a Point Fiducial‐Based Model for the Prostatic Bed in Post‐Prostatectomy Radiation Therapy Patients: An Expedited Dosimetric Analysis Using New Functionality in Philipsˈ Pinnacle3 Treatment Planning Systemˈs Research Version (2011) (0)
SU‐GG‐T‐385: QuASA2R — a Digital Data Quality Assurance Submission, Archive, Analysis, and Review System for Advanced Technology Clinical Trials in Radiation Therapy (2008) (0)
WE‐G‐BRB‐04: Leveraging Innovation to Design Future Clinical Trials (2015) (0)
A Multi-Institutional Evaluation of Electronic Incident Reports: Anticipating a National Reporting System (2011) (0)
SP-0245: Is it time to design specific radiotherapy trials for the elderly, and how can we integrate the economic perspective? (2010) (0)
A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP). (2017) (0)
Five-year patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer. (2022) (0)
SP-0484: First two years clinical experience with low-field MR-IGRT-system practicality and future implications (2016) (0)
OC-0246: Clinical implementation of online MR-guided adaptive radiotherapy for abdominopelvic malignancies (2015) (0)
Overview of Image-Guided Localization Modalities (2008) (0)
MP51-10 PREDICTORS OF FAVORABLE URINARY OUTCOMES AFTER PROSTATE CANCER TREATMENT (2014) (0)
Quality improvements in radiation oncology clinical trials (2023) (0)
Online Adaptive MR Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages (2015) (0)
Association of Black Race With Improved Outcomes Following Definitive Radiotherapy With Androgen Deprivation Therapy for High-Risk Prostate Cancer: A Meta-Analysis of Eight Randomized Trials (2020) (0)
Individual Margin Determination for Prostate Cancer Patients undergoing Real-time Tracking (2008) (0)
1115: Age as an Independent Prognostic Factor in Patients With Glioblastoma: A Radiation Therapy Oncology Group Analysis (2006) (0)
853 poster PEDIATRIC INTRACRANIAL EPENDYMOMA: OUTCOME AND PATTERNS OF FAILURE FOLLOWING POST-OPERATIVE RADIOTHERAPY (2011) (0)
Improved Dosimetric Accuracy of Bulk Density Overridden Plans for Prostate Patients Using Tissue Population Average Electron Densities Obtained Within Radiation Beam Paths (2013) (0)
Magnetic Resonance Image Guided Radiation Therapy (MR-IGRT) for the Treatment of Prostate Cancer: Initial Clinical Experience and Patient Selection (2016) (0)
824: Neoadjuvant Hormone Therapy (NHT) Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multi-Center Prospective Study (2005) (0)
In regard to: Does the evidence support the enthusiasm over 3D conformal radiation therapy and dose escalation in the treatment of prostate cancer? Authors' reply (2002) (0)
CMS-08NEUROPSYCHOLOGICAL FUNCTIONING IN CHILDREN WITH MEDULLOBLASTOMA: THE IMPACT OF CEREBELLAR MUTISM WITHIN THE FIRST YEAR FOLLOWING DIAGNOSIS (2016) (0)
MR Image-Guided Adaptive Radiotherapy : First Clinical Applications (2015) (0)
Radiation Oncology and Radiopharmaceuticals: Making Our Own History While Learning From the Past. (2023) (0)
A Survey of the ITC Volumetric Treatment Planning Data Archive Supporting RTOG Advanced Technology Clinical Trials (2007) (0)
1764: Long-term Toxicity following 3D Conformal Radiation Therapy for Prostate Cancer on RTOG 9406, a Phase I/II dose Escalation Study (2007) (0)
Transitioning from Old Cobalt-60 Teletherapy to Modern Linac Radiotherapy in a Lower-Middle Income Country Guatemala (2020) (0)
Association of survival and local radiotherapy to the bladder versus chemotherapy alone for patients with metastatic urothelial carcinoma (mUC). (2021) (0)
NCOG-15. LONG-TERM IMPACT OF RADIATION DOSE AND VOLUME ON INTELLECTUAL FUNCTIONING (IQ) FOR CHILDREN DIAGNOSED WITH MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG) (2017) (0)
Short-Term Adjuvant versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Randomized Phase 3 Trials (2020) (0)
1103 SURVIVAL ANALYSIS AFTER PROSTATE CANCER TREATMENT AMONG HEALTHY MEN: MULTI-INSTITUTIONAL STUDY OF 6692 PATIENTS (2011) (0)
Vector analysis of bladder cancer patient setup utilizing a magnetic resonance image-guided radiation therapy (MR-IGRT) system. (2016) (0)
SP-0620: In-room MR image-guided plan of the day (2016) (0)
Adherence of United States Insurance Payer Policies to American Society of Radiation Oncology (ASTRO) Stereotactic Radiosurgery (SRS) Model Policy. (2020) (0)
Abstract 110: Colon Cancer in Patients under 50 in Guatemala: A Retrospective Comparative Cohort Study (2021) (0)
Detecting a Survival Benefit to Dose Escalation-Reply. (2019) (0)
Interstitial implant alone with or without external beam radiation therapy for intermediate risk localized prostate cancer: Patterns of Care Study in the United States (2006) (0)
OC-0159 Long-Term Results of RTOG 0321: HDR Brachytherapy and External Beam Radiotherapy for Prostate Cancer (2019) (0)
The American Board of Radiology Online Longitudinal Assessment Part 3 Maintenance of Certification Instrument: Rationale and Summary of 6-Month Experience (2020) (0)
Development and Validation of an Automated IMRT Treatment Planning Algorithm (2009) (0)
Investigation Into the Feasibility of Having Uniform Compliance Dosimetric Criteria Across Radiation Therapy Treatment Modalities for NRG Oncology/RTOG 0938 by Using Machine Learning (2016) (0)
Risk Factors for Grade 2+ Late Bladder Toxicity among Patients Treated on Protocol RTOG 94-06 (2008) (0)
UTILIZATION OF MEDICATIONS AND DEVICES FOR ERECTILE DYSFUNCTION AFTER PROSTATE CANCER TREATMENT: RESULTS FROM THE MULTICENTER PROSTQA CONSORTIUM (2009) (0)
Appreciation of 2018 Peer Reviewers for Practical Radiation Oncology. (2019) (0)
The Phoenix Definition of Biochemical Failure Correlates With Clinical Failure for Men Treated With Adjuvant and Salvage Post-Prostatectomy Radiation: Results of the Multi-institutional Pooled Analysis (2007) (0)
Early Quality of Life (QOL) Declines Correlate With Later QOL After Intensity Modulated Radiation Therapy, Low-Dose-Rate Brachytherapy, or Stereotactic Radiation for Prostate Cancer (2014) (0)
Comparison of MRI-based treatment planning with transrectal ultrasound for LDR brachytherapy in prostate cancer (2008) (0)
The Role of MRI-Guided Radiation Therapy for Palliation of Mobile Abdominal Cancers: A Report of Two Cases (2021) (0)
Cost-Effectiveness Analysis of Proton Versus Photon Therapy With Respect to Risk of Growth Hormone Deficiency (2014) (0)
Comparison of Radiation Necrosis in Adult Cranial Oligodendrogliomas and Astrocytomas Treated With Proton Versus Photon Therapy (2017) (0)
QOL-20. IMPACT OF RADIATION DOSE AND VOLUME ON MEMORY FUNCTIONING IN CHILDREN WITH MEDULLOBLASTOMA: A REPORT FROM CHILDREN’S ONCOLOGY GROUP (COG) ACNS0331 (2020) (0)
The Impact of Persistently Elevated PSA after Prostatectomy in Men with Recurrent Prostate Cancer in NRG Oncology/RTOG 9601 (2020) (0)
National Radiation Oncology Registry: The pilot prostate cancer registry. (2012) (0)
Comparison of two portal image alignment methods for treatment verification analysis (1992) (0)
Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study. (2021) (0)
SU‐E‐J‐169: CT Simulation Optimization for Prostate Cancer Patients in Radiation Therapy: A General Strategy (2013) (0)
WE‐D‐204C‐01: Opportunities and Considerations for Multi‐institutional Clinical Trials Research (2010) (0)
PO-0859: Quantifying and categorizing plan rejections as a part of the clinical process improvement (2016) (0)
1298 poster STANDARDIZING NAMING CONVENTIONS IN RADIATION THERAPY (2011) (0)
Treatment Results with External Beam Radiation Therapy for Localized Carcinoma of the Prostate (Stages T1b, T2, and T3) (1996) (0)
AR enhancer and locus genomic alterations as cell-free DNA biomarkers of primary resistance to AR-directed treatment of metastatic prostate cancer. (2020) (0)
152 Inter-treatment compensation of treatment setup variation to enhance the radiotherapeutic ratio (1995) (0)
Radium-223 dichloride (Ra-223) hematologic and 1.5-year posttreatment safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from ALSYMPCA (2014) (0)
Clinical trials and radiation oncology technologies. (2009) (0)
A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415. (2020) (0)
Genomic classifier performance in intermediate-risk prostate cancer: Results from NRG Oncology/RTOG 0126 randomized phase III trial. (2023) (0)
Year One of the First Ever MR-IGRT Program: System Practicality and Future Implications (2015) (0)
Magnetic resonance image-guided radiation therapy (MR-IGRT) for the treatment of prostate cancer: Initial clinical experience and patient selection. (2016) (0)
A Framework for Accumulating True Dose (DA) in MR-IGRT (2015) (0)
Propensity score matched analysis of metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy or radical prostatectomy. (2015) (0)
Utilization and survival outcomes between definitive versus conservative treatments among elderly men with high-risk prostate cancer. (2021) (0)
A Multi-institutional Phase 2 Trial Assessing Quality of Life (QOL) After Electromagnetic Transponder Guided Prostate Stereotactic Body Radiation Therapy (SBRT) (2015) (0)
261 Dosimetric considerations in the outcome of medulloblastoma (1995) (0)
Head and neck quality assurance 2014 (2016) (0)
Outcomes and patient-related reported urinary toxicity of low dose rate brachytherapy for localized prostate cancer. (2016) (0)
Integrated clinicopathologic and molecular risk stratification for disease recurrence in muscle-invasive bladder cancer. (2021) (0)
EP-1749: The IROC QA Center's Activities Supporting the NCI's National Clinical Trial Network (2017) (0)
A treatment planning comparison of proton therapy and intensity-modulated radiotherapy (IMRT) for prostate cancer using the normal tissue complication probability (NTCP). (2016) (0)
Oral Scientific SessionsMulti-institutional Outcomes of Postprostatectomy Adjuvant Versus Early Salvage Radiation Therapy in Prostate Cancer Patients With Adverse Pathologic Features (2017) (0)
Geometric Variation in Gastrointestinal Organs-At-Risk in MR-Guided Online Treatment Adaptation (2018) (0)
A Feasibility Study and Optimization of Dosimetric Objective with Heterogeneity Corrections for RTOG Studies with Hypo-fractionated Stereotactic Radiotherapy of Lung Cancers (2009) (0)
Predictive assays in medulloblastoma (1992) (0)
Moody D. Wharam Jr, MD, FACR, FASTRO, July 22, 1941-August 10, 2018. (2019) (0)
Nomogram predicting treatment-related bowel dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI). (2012) (0)
Neoadjuvant Hormone Therapy (NHT) Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multi-Center Prospective Study (2005) (0)
Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis. (2018) (0)
Stereotactic MR-Guided Adaptive Radiotherapy (SMART) for Ultra-Central Thorax Lesions: Results of a Phase 1 Trial (2017) (0)
Appreciation of 2018 peer reviewers for Practical Radiation Oncology. (2019) (0)
162 Quality assurance of 3-D conformal radiation therapy for a cooperative group trial — RTOG 3D QA center initial experience (1996) (0)
Evaluation of 3T Pelvic MRI Imaging in Prostate Cancer Patients Receiving Postprostatectomy IMRT (2013) (0)
Longitudinal predictive ability of mapping algorithms: Secondary analysis of NRG Oncology/RTOG 0415. (2021) (0)
Dose Response for Salvage Radiation Therapy After Radical Prostatectomy in Margin-Positive Prostate Cancer (2015) (0)
Comparison of Motion Induced Dose Decrement between Prone and Supine Prostate Radiotherapy (2010) (0)
EP-1221: Evaluation of 3-Tesla pelvic MRI in prostate cancer patients receiving post-prostatectomy IMRT (2015) (0)
Analysis of Brachytherapy Plans for Regulatory Compliance: Dosimetric Study of RTOG 0232 Plans to Quantify Expected Dose to Organs at Risk (2011) (0)
Comparison of weekly port films and on-line portal images in estimating treatment variation (1993) (0)
Effectiveness of adjuvant radiotherapy after radical cystectomy for locally advanced bladder cancer. (2018) (0)
Incidence of Radiation Pneumonitis after a Single 550 cGy Fraction of Total Body Irradiation: Single Institutional Experience (2022) (0)
Long-term Follow-up after Radiotherapy for Prostate Cancer with and without Rectal Hydrogel Spacer: A Pooled Prospective Evaluation of Sexual Function of Men with Good Baseline Sexual Function (2019) (0)
The Imaging and Radiation Oncology Core (IROC) Effort for the NCI National Clinical Trial Network (NCTN) (2015) (0)
Patterns of failure in medulloblastoma after optimal radiation therapy (2003) (0)
SU‐GG‐J‐108: Validation Study of a Software Tool for Consensus Analysis of Experts' Contours for Generating Atlases of Radiotherapy Target and Normal Structures (2010) (0)
Dose Escalation Using a Hydrogel Spacer for Intensity Modulated Radiation Therapy in Prostate Cancer (2015) (0)
SU‐FF‐J‐33: Image Guided Radiotherapy in Prostate Localization: A Comparison of Ultrasound Modalities to Implanted Seed Markers and Assessment of Intrafractional Prostate Motion (2007) (0)
Comparative Effectiveness Analysis of Patient-Reported Quality of Life (QOL) After Stereotactic Body Radiation Therapy as Compared to Intensity Modulated Radiation Therapy or Low-Dose-Rate Brachytherapy up to 2 Years After Treatment (2014) (0)
Rebuttal to Drs. Hussein and Cooperberg. (2015) (0)
TH‐AB‐BRB‐09: Effect of Hydrogel Spacer On Achievable Rectal DVH for IMRT in Prostate Cancer (2015) (0)
Impact of facility patient volume on overall survival in patients with muscle invasive bladder cancer undergoing trimodality bladder preservation therapy. (2019) (0)
High-Dose RT Does Not Improve OS in Prostate Cancer (2014) (0)
Defining Long Term Failure Risk in Patients With an Undetectable PSA After Salvage Radiation (2014) (0)
Who Benefits From a Prostate Rectal Spacer?: Secondary Analysis of Dosimetry and Bowel Quality of Life From a Phase III Trial (2018) (0)
Benefit of Elective Nodal Irradiation and Androgen Deprivation Therapy with Postprostatectomy Salvage Radiation Therapy for Prostate Cancer (2016) (0)
11C-Acetate-PETを用いた前立腺癌再発診断 (2002) (0)
Providing practitioner-specific outcomes is associated with higher patient satisfaction with information about prostate cancer treatment. (2006) (0)
Point/Counterpoint Rebuttal to Drs. Hussein and Cooperberg (2015) (0)
MBCL-07. 5-YEAR EVENT-FREE SURVIVAL (EFS) AND NEUROCOGNITIVE OUTCOME IN CHILDREN WITH MEDULLOBLASTOMA (MB) BETWEEN 3 AND 5 YEARS OF AGE: RESULTS OF CHILDREN’S ONCOLOGY GROUP STUDY ACNS0331 (2018) (0)
PREDICTING URINARY FUNCTION AFTER PROSTATE CANCER TREATMENT: A MULTIVARIABLE NOMOGRAM FROM THE PROSTQA CONSORTIUM (2009) (0)
Acknowledgement of reviewers 2012 (2013) (0)
(P22) A Propensity Analysis Comparing Definitive Chemo-Radiotherapy for Squamous Cell Carcinoma of the Bladder vs. Urothelial Carcinoma of the Bladder Using the National Cancer Database (2018) (0)
Survival outcomes in elderly patients with muscle invasive bladder cancer: An analysis of the National Cancer Database. (2017) (0)
PD-0422: Validating a 2 year survival prediction model for laryngeal carcinoma patients in a clinical care and trial setting (2015) (0)
SP-0102: On-board MR image guidance for adaptive therapy (2015) (0)
Neoadjuvant versus concurrent androgen deprivation therapy plus radiotherapy for unfavorable intermediate-risk and high-risk prostate cancer with low PSA. (2021) (0)
In response to Drs. Levitt and Khan (2002) (0)
Establishing a Radiation Oncology Quality Surveillance Program (2019) (0)
Risk of Biochemical Failure in Patients With High-Risk Prostate Cancer Treated Definitively or Postoperatively With Intensity Modulated Radiation Therapy (2013) (0)
Is the Prostatic Bed a Rigid Structure? Evaluation Using Real-time Electromagnetic Tracking (2012) (0)
Effect Of Hormone Therapy Within Risk Groups Defined By Generalized Competing Event Model: Ancillary Analysis Of NRG Oncology’s RTOG 9408 (2020) (0)
1671: Association of Race, Cancer Severity, Pre-Treatment Quality of Life, and Patient Optimism/Pessimism with Patient Selection of Primary Prostate Cancer Treatment (2005) (0)
EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP ACNS0332 TRIAL (2018) (0)
Larry Emanuel Kun, March 10, 1946-May 27, 2018. (2019) (0)
Analysis Of Brachytherapy Plans For Regulatory Compliance: Application Of Expected Doses To Organs At Risk (2011) (0)
Local/regional failure in patients with rhabdomyosarcoma (rms) and microscopic residual disease (2001) (0)
The Influence of the Pretreatment Host Immune State on Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521 (Updated) (2020) (0)
Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience (2017) (0)
(P097) Two-and-a-Half Year Clinical Experience With Magnetic Resonance Image Guided Radiation Therapy (2017) (0)
Plan Performance Using a Prototype Auto-Planning Workflow within a Novel Treatment Planning System (2019) (0)
Remote Global Radiation Oncology Education and Training: A Pathway to Increase Access to High-Quality Radiation Therapy Services in Low- and Middle-Income Countries (2023) (0)
Multi-institutional Prospective Evaluation of Bowel Quality of Life after Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated with Patient Reported Outcomes (2011) (0)
Quality, Value, and the Assessment of New Technology (2016) (0)
694 ALLEVIATION VERSUS INDUCTION OF URINARY OBSTRUCTION OR INCONTINENCE BY PROSTATE CANCER TREATMENT THE PIVOTAL ROLE OF PRETREATMENT URINARY SYMPTOMS (2012) (0)
Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: A pooled prospective evaluation of quality of life. (2019) (0)
Dermatofibrosarcoma ProtuberansPractice Guidelines in Oncology (2012) (0)
Late Breaking Abstracts LBA 1 Two Years of AntiAndrogen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy : A Secondary Analysis of the NRG Oncology / RTOG 9601 Randomized Phase III Trial (2019) (0)
MRI-Guided Radiation Therapy for Bladder: Initial Experience (2015) (0)
Response to Drs. Epp and Suit (1994) (0)
Teaching Case First Reported Case of Pediatric Radiation Treatment With Magnetic Resonance Image Guided Radiation Therapy (2019) (0)
Impact of Industrial Systems Design Applications on Process Improvement and Patient Safety in Radiation Therapy (2008) (0)
OC-1030: Salvage LDR Prostate Brachytherapy: Results of NRG/RTOG-0526 Trial for Local Recurrence after EBRT (2020) (0)
PSA screening for colorectal cancer patients: proceeding with caution. (2013) (0)
Practice-Based Evidence to Evidence-Based Practice: Initial Challenges in Building the NROR (2013) (0)
Patient-reported Quality of Life in Prostate Cancer Patients Treated With 3D Conformal Intensity Modulated or Proton Beam Radiation Therapy (2012) (0)
Deformable Imaging Capability for the Radiation Therapy Oncology Group (RTOG) Consensus Atlas of Musculoskeletal Anatomy (CAMAS) for Soft Tissue Sarcoma of the Lower Extremities. (2013) (0)
RONC-27. PROTON THERAPY REDUCES DOSE TO CRITICAL CENTRAL NERVOUS SYSTEM STRUCTURES IN MEDULLOBLASTOMA: A DOSIMETRIC ANALYSIS OF CHILDREN’S ONCOLOGY GROUP (COG) ACNS0331 (2020) (0)
1136: Which Definition of Biochemical Failure after Post-Operative Radiotherapy Predicts Best for Clinical Failure? A Multi-Institutional Analysis (2005) (0)
167 : RTOG Participating Physician and Research Associates Attitudes Regarding Clinical Trials: Implications for Improving Recruitment (2006) (0)
SU‐FF‐T‐55: Variability of Prostate Brachytherapy Preimplant Dosimetry: A Multi‐Institutional Analysis (2005) (0)
Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. (2012) (0)
Cost-effectiveness analysis of proton versus photon therapy with respect to risk of growth hormone deficiency. (2013) (0)
RADIATION THERAPY ONCOLOGY GROUP RTOG 98-03 PHASE I/II RADIATION DOSE ESCALATION STUDY APPLYING CONFORMAL RADIATION THERAPY IN SUPRATENTORIAL GLIOBLASTOMA MULTIFORME (2003) (0)
The Influence of the Pretreatment Host Immune Inflammatory State and Response to Radiation Therapy in High-Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521 (2018) (0)
Radiation Therapy for Carcinoma of the Renal Pelvis and Ureters (1999) (0)
Quality of Life of Patients Treated with Radiotherapy in an Upper Middle-Income Country (2022) (0)
Pathology Review Documentation in the Electronic Medical Record Prior to Radiation Therapy (2019) (0)
1: Determinants of Satisfaction with Outcome in a Prospective, Multi-Center Study of Prostatectomy, External Radiotherapy, or Brachytherapy for Early Stage Prostate Cancer (2007) (0)
Deformable Imaging Capability for the Radiation Therapy Oncology Group (RTOG) Consensus Atlas of Musculoskeletal Anatomy (CAMAS) for Soft Tissue Sarcoma of the Lower Extremities (2011) (0)
Outcome for Clinical Group III Rhabdomyosarcoma Patients Who Did Not Receive Radiotherapy on IRS-III and -IV (2005) (0)
2089 Initial experience with acqsim CT simulator (1995) (0)
The World’s First Single-Room Proton Therapy Facility—Two-Year Experience (2016) (0)
Dynamic Jaws and Dynamic Couch Tomotherapy for High Risk Prostate Cancer (2010) (0)
PD15-02 LONG-TERM HEALTH RELATED QUALITY OF LIFE IN PROSTATE CANCER PATIENTS REQUIRING RADIOTHERAPY AFTER RADICAL PROSTATECTOMY (2023) (0)
Serum Testosterone Levels in Men Treated With Intensity Modulated Radiation Therapy for Prostate Cancer (2012) (0)
Preliminary evaluation of a non-invasive ultrasound prostate localization device (2000) (0)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Brain Tumor Committee. (2001) (0)
First-in-human Use of Linear Accelerator Gating with Electromagnetic Tracking (2011) (0)
Imaging and Neuro-Oncology Clinical Trials of the National Clinical Trials Network (NCTN) (2019) (0)
Angiosarcoma: History of Prior Radiation Therapy is an Adverse Prognostic Factor (2018) (0)
Basal cell and squamous cell skin cancers. (2010) (0)
Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials. (2020) (0)
Abstract LB-269: Detection of cell-free DNA alterations in AR and its enhancer significantly outperformed CTC AR-V7 detection for identifying treatment resistance in patients with metastatic prostate cancer (2020) (0)
Survival Outcomes in Elderly Patients with Muscle Invasive Bladder Cancer: A Population Based Analysis (2017) (0)
Initial Evaluation of the First Commercially Available Knowledge-Based Planning Software (2014) (0)
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jeff Michael Michalski?

Jeff Michael Michalski is affiliated with the following schools:

Medical College of Wisconsin

Jeff Michael Michalski's Academic­Influence.com Rankings

Why Is Jeff Michael Michalski Influential?

Jeff Michael Michalski's Published Works

Published Works

What Schools Are Affiliated With Jeff Michael Michalski?

Jeff Michael Michalski's AcademicInfluence.com Rankings